Related Experiment Video
Updated: Apr 3, 2026
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
Helicobacter pylori Eradication Primary Care First-Line Prescriptions: Data From 200,000 Patients in a Real-World
Encarnación Fernández-Antón1,2, Olga P Nyssen3, Gabriela Alonso-Martínez1,2
1Department of Biomedical Sciences (Pharmacology), School of Medicine and Health Sciences, University of Alcalá (IRYCIS), Alcalá de Henares, Spain.
Background:
Helicobacter pylori is a common infection primarily managed in primary care. Assessing real-world practices and guideline adherence is crucial for treatment optimisation. The study aims to assess current H. pylori management strategies using data from BIFAP, a Spanish primary care database.
Materials And Methods:
Cohort study including patients aged ≥ 18 with recorded H. pylori infection (2003-2023) and corresponding treatment prescriptions. Infection cases were identified using ICD-9/10 and SNOMED-CT codes. Treatment patterns were based on Spanish and European guidelines. First-line treatment prescriptions were compared between primary (BIFAP) and specialized (European Registry, Hp-EuReg) care.
Results:
A total of 211,972 H. pylori-infected subjects were identified. Over the study period (20 years), the predominant first-line treatments were: bismuth quadruple therapy including a proton-pump inhibitor (PPI) plus a single capsule containing bismuth-tetracycline-metronidazole (36%); PPI + clarithromycin-amoxicillin (30%); and PPI + clarithromycin-amoxicillin-metronidazole (26%). Single-capsule bismuth quadruple therapy was the most common in patients aged 18-64 and those with obesity, chronic kidney disease, or smokers, while PPI + clarithromycin-amoxicillin was more common in those aged ≥ 65 or with peptic ulcers. Since 2013, PPI + clarithromycin-amoxicillin use by general practitioners and gastroenterologists decreased, though it remained above 10% in primary care at study end. PPI + clarithromycin-amoxicillin-metronidazole increased since 2015, with higher use in specialized care (40%) vs. primary care (30%). In 2023, single-capsule bismuth quadruple therapy was the most prescribed regimen in both settings, accounting for ~60% of prescriptions.
Conclusions:
Primary care H. pylori treatments are varied, with single-capsule bismuth quadruple therapy most prescribed. Guidelines are followed, but adoption is slower in primary than in specialized care.
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
01:27Peptic Ulcer
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.